Transcriptomic data have shown that angiogenesis and immune activities are exclusively enriched in the Alveolar Soft Part Sarcoma Chromosome Region, Candidate 1–Transcription factor E3 (ASPSCR1-TFE3) in renal cell carcinoma (rRCC), suggesting the superior clinical outcomes of ICIs and TKI combination therapy [138]. Here, TFE3 is linked to hereditary clear cell renal cell carcinoma.